Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. (Q52558663)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

title

Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Amy M Lehman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

Lakshmanan Annamalai

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

Jennifer H Yearley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

Konstantin Shilo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

Gregory A Otterson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

publication date

24 April 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

25 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

1204-1212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

25 March 2020

cites work

1 reference

12 December 2020

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

1 reference

12 December 2020

WHO histologic classification is a prognostic indicator in thymoma

1 reference

12 December 2020

Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report

1 reference

12 December 2020

Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma

1 reference

12 December 2020

Comparison of patterns of relapse in thymic carcinoma and thymoma

1 reference

12 December 2020

Thymoma and thymic carcinoma

1 reference

12 December 2020

Epidemiology of Thymoma and Associated Malignancies

1 reference

12 December 2020

Staging System of Thymoma

1 reference

12 December 2020

Management of stage I and II thymoma

1 reference

12 December 2020

Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma

1 reference

12 December 2020

Combination Chemotherapy with Carboplatin and Paclitaxel for Advanced Thymic Cancer

1 reference

12 December 2020

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

1 reference

12 December 2020

Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging

1 reference

12 December 2020

Diffuse high intensity PD-L1 staining in thymic epithelial tumors

1 reference

12 December 2020

A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.

1 reference

12 December 2020

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

1 reference

12 December 2020

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

1 reference

12 December 2020

Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis

1 reference

12 December 2020

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

12 December 2020

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

1 reference

12 December 2020

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes

1 reference

12 December 2020

Surgical treatment of thymoma: an 11-year experience with 761 patients

1 reference

12 December 2020

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma

1 reference

12 December 2020

Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases

1 reference

12 December 2020

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.

1 reference

12 December 2020

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.

1 reference

12 December 2020

Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.

1 reference

12 December 2020

Response to Pembrolizumab in a Patient with Relapsing Thymoma

1 reference

12 December 2020

Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases

1 reference

12 December 2020

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.

1 reference

12 December 2020

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

12 December 2020

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 December 2020

PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus

1 reference

12 December 2020

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors

1 reference

12 December 2020

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.

1 reference

12 December 2020

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

1 reference

12 December 2020

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

1 reference

12 December 2020

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients

1 reference

12 December 2020

Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.

1 reference

12 December 2020

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

1 reference

12 December 2020

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

1 reference

12 December 2020

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

1 reference

12 December 2020

Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.

1 reference

12 December 2020

Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors

1 reference

12 December 2020

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

1 reference

12 December 2020

Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification

1 reference

12 December 2020

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

1 reference

12 December 2020

10.1016/J.JTHO.2018.04.013

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29702286 AND SRC:MED&resulttype=core&format=json

25 March 2020

1 reference